Pacific Biosciences Of California (PACB) EBITDA (2010 - 2026)

Pacific Biosciences Of California's EBITDA history runs 17 years deep, the most recent figure standing at -$8.4 million for Q1 2026.

• On a quarterly basis, EBITDA rose 98.05% year-over-year to -$8.4 million in Q1 2026; TTM through Mar 2026 was -$133.3 million, a 83.78% increase from a year earlier, with the FY2025 full-year figure at -$553.9 million, down 16.77% from the prior year.
• EBITDA improved to -$8.4 million in Q1 2026 per PACB's latest filing, from -$41.2 million in the prior quarter.
• Across five years, EBITDA topped out at -$8.4 million in Q1 2026 and bottomed at -$428.9 million in Q1 2025.
• The 5-year median for EBITDA is -$77.5 million (2022), against an average of -$98.7 million.
• Across the five-year window, EBITDA plunged 427.19% in 2025 and soared 98.05% in 2026, its largest moves.
• Year by year, EBITDA stood at -$87.1 million in 2022, then dropped by 0.53% to -$87.5 million in 2023, then sank by 74.79% to -$153.0 million in 2024, then surged by 73.08% to -$41.2 million in 2025, then surged by 79.71% to -$8.4 million in 2026.
• Per Business Quant, the three latest PACB EBITDA figures stand at -$8.4 million (Q1 2026), -$41.2 million (Q4 2025), and -$38.9 million (Q3 2025).